Literature DB >> 9182048

Setting exposure standards: a decision process.

H A Tilson1, R C MacPhail, K M Crofton.   

Abstract

Increased emphasis on routine screening of chemicals for potential neurotoxicity has resulted in the development of testing guidelines and standardized procedures. A multiphased, tiered-testing strategy has been proposed by numerous expert panels to evaluate large numbers of chemicals. In a regulatory context, however, a formal tiered-testing approach is not used, mostly because of the constraints of differing regulatory authorities and the potential cost of such a testing strategy. Instead, current regulatory decision making utilizes all available animal and human data to identify a critical adverse effect which is then used for setting standards. Although the current decision-making process does not use a formal tiered-testing approach, it appears to identify chemicals with neurotoxic effects. An analysis of U.S. Environmental Protection Agency integrated risk information system (IRIS) indicates that about 20% of the chemicals having standards or health advisories are based on neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9182048      PMCID: PMC1469596          DOI: 10.1289/ehp.96104s2401

Source DB:  PubMed          Journal:  Environ Health Perspect        ISSN: 0091-6765            Impact factor:   9.031


  9 in total

Review 1.  Neurotoxicology in the 1990s.

Authors:  H A Tilson
Journal:  Neurotoxicol Teratol       Date:  1990 Jul-Aug       Impact factor: 3.763

Review 2.  Workshop on the qualitative and quantitative comparability of human and animal developmental neurotoxicity, Work Group IV report: triggers for developmental neurotoxicity testing.

Authors:  T E Levine; R E Butcher
Journal:  Neurotoxicol Teratol       Date:  1990 May-Jun       Impact factor: 3.763

Review 3.  Current status of behavioral teratology: science and regulation.

Authors:  C A Kimmel
Journal:  Crit Rev Toxicol       Date:  1988       Impact factor: 5.635

Review 4.  Scientific and regulatory issues relevant to assessing risk for developmental neurotoxicity: an overview.

Authors:  D C Rees; E Z Francis; C A Kimmel
Journal:  Neurotoxicol Teratol       Date:  1990 May-Jun       Impact factor: 3.763

5.  Reference dose (RfD): description and use in health risk assessments.

Authors:  D G Barnes; M Dourson
Journal:  Regul Toxicol Pharmacol       Date:  1988-12       Impact factor: 3.271

Review 6.  Glutamate neurotoxicity and diseases of the nervous system.

Authors:  D W Choi
Journal:  Neuron       Date:  1988-10       Impact factor: 17.173

7.  Application of the preliminary developmental toxicity screen for chemical hazard identification under the Toxic Substances Control Act.

Authors:  E Z Francis; W H Farland
Journal:  Teratog Carcinog Mutagen       Date:  1987

8.  Neurobehavioral testing of chemicals: impact on recommended standards.

Authors:  W K Anger
Journal:  Neurobehav Toxicol Teratol       Date:  1984 Mar-Apr

Review 9.  Comparison of screening approaches.

Authors:  H A Tilson; V C Moser
Journal:  Neurotoxicology       Date:  1992       Impact factor: 4.294

  9 in total
  4 in total

Review 1.  Neurobehavioral science in hazard identification and risk assessment of neurotoxic agents--what are the requirements for further development?

Authors:  Roberto Lucchini; Elisa Albini; Laura Benedetti; Lorenzo Alessio
Journal:  Int Arch Occup Environ Health       Date:  2005-05-13       Impact factor: 3.015

Review 2.  Animal behavioral methods in neurotoxicity assessment: SGOMSEC joint report.

Authors:  B Kulig; E Alleva; G Bignami; J Cohn; D Cory-Slechta; V Landa; J O'Donoghue; D Peakall
Journal:  Environ Health Perspect       Date:  1996-04       Impact factor: 9.031

Review 3.  Risk assessment for neurobehavioral toxicity: SGOMSEC joint report.

Authors:  D Hattis; J Glowa; H Tilson; B Ulbrich
Journal:  Environ Health Perspect       Date:  1996-04       Impact factor: 9.031

4.  New horizons: future directions in neurotoxicology.

Authors:  H A Tilson
Journal:  Environ Health Perspect       Date:  2000-06       Impact factor: 9.031

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.